WAIKOLOA, Hawaii — In this expert perspective from Retina 2026, Allen C. Ho, MD, director of retina research at Wills Eye Hospital, said 2026 is going to be a “really big year” in retina.
According to Ho, topline results are expected for tyrosine kinase inhibitors from EyePoint Pharmaceuticals and Ocular Therapeutix. Results are also expected on subretinal gene therapy from AbbVie and Regenxbio on sura-vec for biofactory production of anti-VEGF therapy for neovascular age-related macular degeneration.
“I’m looking forward to these potential management-changing